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Abstract 
Purpose: The intestinal microbiota has emerged as a virtual organ with essential functions in human physiology. 
Antibiotic-induced disruption of the microbiota in critically ill patients may have a negative influence on key energy 
resources and immunity. We set out to characterize the fecal microbiota composition in critically ill patients both with 
and without sepsis and to explore the use of microbiota-derived markers for clinical outcome measurements in this 
setting.
Methods: In this prospective observational cohort study we analyzed the fecal microbiota of 34 patients admitted to 
the intensive care unit. Fifteen healthy subjects served as controls. The fecal microbiota was phylogenetically charac-
terized by 16S rRNA gene sequencing, and associations with clinical outcome parameters were evaluated.
Results: A marked shift in fecal bacterial composition was seen in all septic and non-septic critically ill patients com-
pared with controls, with extreme interindividual differences. In 13 of the 34 patients, a single bacterial genus made 
up >50% of the gut microbiota; in 4 patients this was even >75%. A significant decrease in bacterial diversity was 
observed in half of the patients. No associations were found between microbiota diversity, Firmicutes/Bacteroidetes 
ratio, or Gram-positive/Gram-negative ratio and outcome measurements such as complications and survival.
Conclusions: We observed highly heterogeneous patterns of intestinal microbiota in both septic and non-septic 
critically ill patients. Nevertheless, some general patterns were observed, including disappearance of bacterial genera 
with important functions in host metabolism. More detailed knowledge of the short- and long-term health conse-
quences of these major shifts in intestinal bacterial communities is needed.
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Introduction
While antibiotics are one of the greatest inventions of the 
twentieth century, their potential side effects are being 
increasingly recognized. In addition to concerns on the 
emergence of bacterial resistance, it has been suggested 
that antibiotic-induced changes to the intestinal flora 
could have serious and long-lasting consequences for 
human physiology [1, 2]. Paradoxically, antibiotic treat-
ment can increase susceptibility to opportunistic and 
nosocomial infections by affecting the resistance of the 
intestinal microbiota to colonization [3]. A low-diversity 
community with limited resilience allows pathogens like 
Clostridium difficile and vancomycin-resistant entero-
cocci to grow unrestrictedly [4]. Additionally, decreased 
gut microbial diversity has been associated with patho-
genic conditions, such as inflammatory bowel disease 
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and increased mortality following allogeneic hematopoi-
etic stem cell transplantation (HSCT) [2, 5]. Physiologi-
cal functions of the microbiota, such as the metabolism 
of carbohydrates and production of vitamins, may be lost 
as well.
A decreased gut microbial diversity could be of par-
ticular relevance for critically ill patients, as the vast 
majority of patients in an intensive care unit (ICU) are 
treated with antibiotics. A prospective point prevalence 
study involving 1265 ICUs across the world found that 
on any given day 75% of patients admitted to these ICUs 
received antibiotics [6]. In The Netherlands, systemic 
decontamination of the digestive tract (SDD), consisting 
of topical application of non-absorbable antibiotics and 
a short course of systemic cephalosporins, is common 
practice in ICUs [7, 8]. SDD is a much-debated policy, 
with reduced infection rates and mortality as potential 
benefits and increased antimicrobial resistance as poten-
tial drawback. While the aim of SDD is to prevent colo-
nization with potential pathogenic microorganisms while 
preserving anaerobic bacteria, its effect on the composi-
tion of the intestinal microbiota as a whole is ill-defined.
Recent advances, such as the implementation of fecal 
transplantation as therapy for C. difficile infection, sug-
gest that it may be possible to monitor, prevent, or even 
cure disease by modulating the intestinal microbiota 
[9–11]. First, however, more knowledge is needed on the 
composition of the gut microbiota in critically ill patients 
to better understand the clinical consequences of micro-
biota disturbances and thus determine which patients 
might benefit from microbiota-based therapies [9].
Based on previous studies, we hypothesized that 
microbial diversity would be extremely low in critically ill 
patients and that low diversity would be associated with 
worse clinical outcome [5, 12, 13]. In this pilot study we 
describe the phylogenetic composition of the fecal micro-
biota in a cohort of critically ill patients using 16S rRNA 
gene sequence analysis and compare the results in both 
septic and non-septic critically ill patients with those in 
healthy subjects. We also explored possibilities to cor-
relate microbiota-derived markers with clinical outcome 
parameters.
Methods
Subjects
This study was part of a large prospective observational 
study in critically ill patients admitted to the ICU [Molec-
ular Diagnosis and Risk Stratification of Sepsis (MARS) 
study; clinicaltrials.gov identifier NCT01905033] [14]. 
Thirty-four randomly selected adult patients who were 
admitted to the ICU of the Academic Medical Center 
(Amsterdam, The Netherlands) between October 2012 
and November 2013 were included. Patients who were 
transferred from other ICUs or had an expected length of 
ICU stay of <24 h were excluded. All patients met at least 
two of the following criteria: body temperature of ≤36 or 
≥38 °C, tachycardia of >90/min, tachypnea of >20/min or 
partial pressure of carbon dioxide (pCO2) of  <  4.3 kPA, 
and leukocyte count of  <4  ×  10E9/L or  >12  ×  10E9/L 
[15]. Sepsis was defined when the inclusion criteria were 
associated with suspected infection within 24  h after 
ICU admission, with subsequent systemic therapeutic 
administration of antibiotics to the patient [15]. Sequen-
tial Organ Failure Assessment scores were recorded daily. 
Definitions of acute kidney injury (AKI) or acute res-
piratory distress syndrome (ARDS) were used exactly as 
described previously [16, 17]. Data from the municipal 
personal records database were used to calculate long-
term survival. The control group consisted of15 healthy, 
non-smoking human subjects who had not taken antibi-
otics during the previous year (ClinicalTrials.gov identi-
fier NCT02127749) [18]. Written informed consent was 
obtained from all healthy subjects and patients or their 
legal representative. Ethical approval for both the patient 
and healthy subject studies was received from the Medi-
cal Ethics Committee of the Academic Medical Center in 
Amsterdam, and all research was conducted in accord-
ance with the declaration of Helsinki.
Intestinal microbiota analysis
Fresh stool samples were stored at 4 °C and transferred to 
−80 °C within 24 h of collection. Samples were processed 
for 16S rRNA gene sequencing exactly as described by 
Lankelma et  al. [18]. DNA was isolated using a bead-
beating protocol [19]. The V1–V2 region of the bacte-
rial 16S rRNA gene was amplified in a two-step protocol 
using universal primers 27F and 338R and sequenced on 
the Illumina MiSeq sequencing platform (Illumina, San 
Diego, CA). Full methods are available in Electronic Sup-
plementary Material (ESM) File 1. The number of reads 
per sample and taxonomic distribution of the reads are 
specified in ESM File 2. A canonical correspondence 
analysis was performed using the Canoco 5 software 
package (Biometris, Wageningen, The Netherlands).
To investigate whether microbiota diversity was asso-
ciated with clinical outcome, we divided the cohort into 
two groups, namely, one with low bacterial diversity 
(Shannon index  < 4.0) and one with normal diversity 
(Shannon index > 4.0). Previous studies have used similar 
arbitrary cutoffs [5, 20]; the present cutoff is based on the 
range of diversity in healthy controls.
Statistical analysis
Continuous nonparametric data were analyzed using a 
Mann–Whitney U or Kruskal–Wallis test, and the results 
are presented as the median and interquartile range 
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(IQR). Continuous parametric data, presented as num-
bers and percentage or as the mean ± standard deviation, 
were analyzed with a student’s t test or analysis of vari-
ance. Categorical data were analyzed using a Chi-square 
test. All data analyses were performed with R studio built 
under R version 3.2.3 (R Core Team 2013; R Foundation 
for Statistical Computing, Vienna, Austria). A p value of 
<0.05 was considered to be statistically significant. Fig-
ures were created using Graphpad Prism (GraphPad 
Software, San Diego, CA).
Results
Patient characteristics
A single fecal sample was collected from 34 critically ill 
patients (mean age 64 years; 48% male) between 1 and 
21  days after ICU admittance [median 4.5 (IQR 2.8–7) 
days; ESM Tables S1 and S2]. Of these 34 patients, 25 
were admitted because of sepsis and one had a non-infec-
tious diagnosis (ESM Table S1). Fifteen healthy subjects 
served as controls.
Microbial composition of fecal samples
Compared to healthy subjects, the stool microbi-
ota showed a highly abnormal composition in most 
patients, based on both the highest bacterial taxonomic 
ranks (phylum level) and lowest detectable ranks (genus 
level).
Phylum level
To obtain a global view of the fecal microbiota in criti-
cally ill patients, we first investigated microbiota com-
position at the phylum level (Fig.  1). Firmicutes and 
Bacteroidetes are the predominant phyla in a stable intes-
tinal microbiota, which was confirmed in our healthy 
subjects with these two phyla combined constituting 
89–98% of all bacteria. However, in 12 of the 34 patients, 
Firmicutes and Bacteroidetes constituted <89% of all bac-
teria and even constituted as low as <1% in one sample 
(p < 0.0001, healthy controls vs. ICU patients). This was 
the case in both septic and non-septic patients. A rela-
tive high abundance of Proteobacteria was observed in 
approximately one-third of patients (p  =  0.02, healthy 
controls vs. ICU patients). This phylum of Gram-negative 
bacteria includes many pathogenic and lipopolysaccha-
ride-containing bacteria, such as Escherichia. There was 
a trend towards an increased ratio of Gram-negative to 
Gram-positive bacteria in ICU patients (p  =  0.0658, 
healthy vs. ICU patients).
Fig. 1 High interindividual diversity in fecal microbiota composition at the phylum level in both septic and non-septic critically ill patients. A single 
fecal sample was collected from septic and non-septic intensive care unit (ICU) patients and healthy subjects. Total bacterial 16S rDNA was isolated 
and sequenced to investigate the bacterial composition of these samples. Each bar represents the microbiota composition of one individual patient 
(patient number indicated at bottom of each bar) at the phylum level, which is the highest bacterial taxonomic rank. Data are presented as the per-
centage of total 16S rDNA reads in each sample; colors indicate different phyla. Patients are grouped according to their main diagnosis. Table shows 
which classes of antibiotics each patient received during their stay in the intensive care unit prior to fecal sampling. Topical P/T/A Topical application 
of polymyxin E, tobramycin, and amphotericin B. None of the healthy subjects had received antibiotics for at least 12 months prior to fecal sampling
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While it is known that intestinal microbiota is highly 
personalized, some very striking individual patterns were 
observed. The fecal sample of patient no. 12 (who had an 
abdominal Escherichia coli sepsis) showed a high abun-
dance of Synergistetes and those of patient nos. 4 and 
18 revealed a high abundance of Verrucomicrobia (dis-
cussed in more detail further in the text.
Genus level
Our analysis of bacterial composition at the genus level 
(ESM Fig. S1) revealed an even greater interpatient 
diversity than that seen at the phylum level. Septic and 
non-septic patients did however share some common 
characteristics when compared to healthy subjects. Most 
notably, several key bacterial genera that each represent 
around 5% of the microbiota in healthy subjects had dis-
appeared almost completely, including Faecalibacterium, 
Blautia, Ruminococcus, Subdoligranulum and Pseudobu-
tyrivibrio (all p < 0.0001, healthy controls vs. ICU patients).
No single bacterial genus colonized >50% of the micro-
biota in the healthy subjects, whereas this did occur in 13 
of the 34 patients, with one genus comprising even >75% 
of the microbiota in four patients (ESM Fig. S1). These 
dominating genera included the usual suspects, such 
as Enterococcus (p  =  0.0002 healthy controls vs. ICU 
patients). Members of Staphylococcus and Escherichia/
Shigella were also significantly more abundant in the 
ICU patients, especially in the abdominal sepsis group 
(p = 0.042 and p = 0.049, respectively, healthy controls 
vs. ICU patients; p = 0.0048 and p = 0.001, respectively, 
healthy controls vs. ICU patients with abdominal sepsis). 
A canonical correspondence analysis to deduce the major 
driving forces in the variability within all microbial data 
indicated that fecal microbiota from abdominal sepsis 
patients differed the most from that of the other patient 
groups (Fig. 2).
Surprisingly, in some patients bacteria belonging 
to Lactobacillus spp. (p  =  0.051, healthy controls vs. 
ICU patients with pulmonary sepsis; p  =  0.06, healthy 
controls vs. ICU patients with abdominal sepsis) and 
Akkermansia spp. (of the phylum Verrucomicrobia; no 
statistically significant correlation with sepsis) were 
abundantly present. Notably, A. muciniphila is known for 
immune stimulation and barrier function improvement 
[21, 22]. The phylum Synergistetes consists of anaerobic 
Gram-negative bacteria that have been associated with 
periodontal disease; those in sample 12 belong to the 
genus Pyramidobacter. The significance of Pyramidobac-
ter in fecal microbiota is as yet unknown, but the oral iso-
late P. piscolens is known to produce hydrogen sulphide, 
which is implied in compromising gut barrier function 
[22, 23]. Overall, the similarity between samples from 
septic patients (Pearson correlation) was significantly 
lower than that of controls (p = 0.0005 healthy controls 
vs. septic patients; Fig. 2).
In patients undergoing allogeneic HSCT, intestinal 
domination by vancomycin-resistant enterococci pre-
cedes bloodstream infection with these bacteria [24]. We 
Fig. 2 High interindividual diversity in septic critically ill patients with sepsis. a Pearson correlations were calculated to investigate the level of 
similarity in microbiota composition between patients with a critical illness of different origin (sepsis originating from lung, abdomen, urinary tract, 
or other location and non-septic critical illness). Patient groups are indicated by colors. Healthy individuals are depicted as additional control group. 
Data are presented as mean ± standard deviation. *p < 0.05, **p < 0.001 vs. healthy controls; p = 0.0005 for all septic patients vs. healthy controls.  
b A canonical correspondence analysis to deduce the major driving forces (Axis 1, Axis 2) in the variability within the microbial data of all ICU 
patients, thereby indicating whether samples are alike (in close proximity to each other) or not (increased distance). The variance is indicated as 
percentages. Symbols/colors represent patient groups as indicated (see a)
63
did not observe any correspondence between intestinal 
abundance and clinical infections (data not shown). Like-
wise, no cases of C. difficile were recorded.
Antibiotics
All patients received SDD consisting of an oral paste 
and solution containing non-absorbable polymyxin E, 
tobramycin, and amphotericin B as well as a third-gen-
eration cefalosporin administered intravenously, unless 
the latter was deemed unnecessary by the treating physi-
cian as the patient was already being treated with another 
broad-spectrum antibiotic (Fig.  1). All septic patients 
were treated with additional antibiotics, varying from 
one to ten different classes of antimicrobial agents (Fig. 1; 
detailed description in ESM Table S2). Septic patients 
were treated with a significantly higher number of anti-
biotic classes than were non-septic critically ill patients 
(p < 0.01), but no differences in microbiota composition 
were observed between these two groups, both at the 
phylum and genus levels.
Association between microbiota composition and clinical 
outcome parameters
To explore whether microbiota-related markers could 
be related to outcome parameters, we used three param-
eters that are commonly used to describe the microbiota, 
namely, bacterial diversity, the Firmicutes/Bacteroidetes 
ratio (F/B-ratio), and the Gram-positive/Gram-negative 
bacteria ratio [5, 11, 25, 26].
We expected ultra-low bacterial diversity in our patient 
cohort based on the exposure of these patients to antibi-
otics and data reported from earlier studies [5, 13]. The 
critically ill patients in our study had significantly lower 
bacterial diversity than the control subjects (p < 0.0001; 
Fig. 3). There was no correlation between the number of 
antibiotic classes that a patient had received and bacte-
rial diversity (Fig.  3), nor between the number of days 
between admission and fecal sampling and bacterial 
diversity (data not shown). When the cohort was divided 
into two groups with low bacterial diversity (Shannon 
index < 4.0) and normal diversity (Shannon index > 4.0), 
there was no intergroup difference in the occurrence of 
complications such as AKI and ARDS or length of ICU 
and hospital stay (Fig.  3; ESM Table S3). In accordance 
with these results, both short- and long-term mortal-
ity were not associated with microbiota diversity. Both 
patient groups were comparable in terms of baseline 
characteristics, severity of disease, and classes of antibi-
otics received prior to fecal sampling (Table 1).
The F/B-ratio was very recently reported to be associ-
ated with survival in critically ill patients [12]. The F/B-
ratio is known to vary widely in healthy subjects [27], 
as was the case in our control subjects whose F/B-ratio 
ranged between 0.5 and 8.4 (median 2.4, IQR 1.1–5.0; 
Fig.  4). In 11 of our 34 patients the F/B-ratio was <0.5, 
indicating a relative increase in Bacteroidetes; in six 
patients, Firmicutes were relatively increased (F/B > 8.4). 
In five patients, no Bacteroidetes were detected at all, and 
the F/B-ratio could not be calculated. There was no dif-
ference in F/B-ratio between survivors and non-survivors 
when plotted at different time points (Fig. 4).
Similar to our results for the F/B-ratio, the Gram-
positive/Gram-negative bacteria ratio varied widely in 
healthy subjects, ranging between 0.5 and 8.0. In 14 
of the 34 patients this ratio was <0.5, indicating a rela-
tive increase in Gram-negative bacteria (Fig.  4). In two 
patients, no Gram-negative bacteria were detected. No 
differences were found between survivors and non-sur-
vivors with respect to the Gram-positive/Gram-negative 
bacteria ratio (Fig. 4).
Discussion
In this pilot study we performed in-depth fecal microbi-
ota analysis in critically ill patients. We observed marked 
shifts in fecal bacterial composition of these patients 
compared to healthy controls. However, a large inter-
individual diversity was observed at both the phylum 
and genus levels. No significant differences in micro-
biota composition were found between patient groups, 
although patients with an abdominal sepsis showed the 
strongest changes in relative abundance of Staphylococ-
cus and Escherichia/Shigella. Low bacterial diversity 
was found in both septic and non-septic patients. In this 
small cohort, we found no associations between micro-
biota diversity, F/B-ratio, or Gram-positive/Gram-nega-
tive bacteria ratio and outcome parameters, such as the 
occurrence of complications or mortality.
A common feature in all critically ill patients was the 
disappearance of genera such as Faecalibacterium, 
Blautia, Ruminococcus, Subdoligranulum, and Pseu-
dobutyrivibrio. These bacteria degrade complex plant 
polysaccharides that human cells cannot break down 
and convert them, for example, into acetate and butyrate, 
the latter of which is an important energy source for 
colonic epithelial cells [22]. It is therefore plausible that 
any microbial disturbance in ICU patients indirectly 
reduces energy resources. Fecal acetate and butyrate have 
been shown to be at significantly lower levels in criti-
cally ill patients compared to healthy controls [28]. The 
disappearance of Faecalibacterium prausnitzii, which has 
known anti-inflammatory properties [25], could poten-
tially promote an unfavorable inflammatory state in the 
gut. A decreased abundance of Faecalibacterium has 
been reported in patients with inflammatory bowel dis-
ease, psoriasis, and colon cancer [29–31]. SDD has also 
been reported to affect the numbers of these bacteria 
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[32]. This decrease in beneficial bacteria is in apparent 
conflict with the potential benefits of SDD in terms of 
decreased ICU-acquired infections and mortality. As the 
aim of SDD is to prevent colonization by potential patho-
gens while preserving anaerobic bacteria, further studies 
are clearly needed to assess the precise influence of SDD 
on the microbiota [32]. It will be essential to take these 
effects into account in the ongoing debate on the use of 
SDD. In-depth knowledge of the fecal microbiota com-
position of ICU patients receiving SDD or not will be an 
important question for follow-up studies.
Knowledge of microbiota changes in critically ill 
patients has been identified as a key objective for ICU 
research [33]. A large retrospective cohort study among 
10,996 participants of the Health and Retirement Study–
Medicare found a strong dose–response relationship 
between events known to result in microbial distur-
bance and subsequent hospitalization for severe sepsis 
[34]. Recent hospitalization for an infection, and espe-
cially C. difficile infection, was associated with a higher 
incidence of rehospitalization for severe sepsis [34]. No 
microbial analyses were performed in this study. In fact, 
Fig. 3 Decreased intestinal microbiota diversity in critically ill patients is not associated with survival in an exploratory setting. a Microbiota diver-
sity, presented as the Shannon index, was calculated from 15 healthy subjects, as well as from all 34 critically ill patients. Data are presented as dot 
plot with the mean (solid horizontal line). ****p < 0.0001. b Shannon diversity from all 34 patient samples plotted against the number of different 
antibiotic classes (categorized as in Fig. 1) that a patient had received prior to fecal sampling. c Based on the range in diversity in healthy subjects, 
the patient cohort was split into two groups: Shannon index <4 (normal diversity) and Shannon index >4 (high diversity), for which a 90-day 
Kaplan–Meier survival plot is shown. Numbers below the curve Patients at risk per group
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surprisingly few studies have addressed the microbiota 
in ICU patients using in-depth sequencing techniques. 
Two small studies of 12 and 14 ICU patients, respectively, 
found large interindividual differences in microbiota 
composition, in line with our findings [12, 13].
A decreased intestinal diversity has been associated 
with numerous pathogenic conditions, ranging from C. 
difficile infection, obesity and inflammatory bowel dis-
ease to increased mortality following allogeneic HSCT [2, 
5, 11]. Our data confirm the expected low bacterial diver-
sity in septic critically ill patients. Strikingly, a similar low 
diversity was observed in non-septic critically ill, despite 
great differences in antibiotic treatment. Antibiotics, pro-
ton-pump inhibitors, radiation, chemotherapeutics, and 
poor nutrition may all contribute to the loss of bacterial 
taxa.
An increased F/B-ratio has been correlated with obe-
sity, asthma, and irritable bowel syndrome [25, 35] and 
Table 1 Baseline characteristics of  patients with  normal or high intestinal microbiota diversity and  use of  antibiotics 
prior to fecal sampling
Data are presented as the median with the interquartile range in square brackets, a number with/without the percentage in parenthesis, or as the mean ± standard 
deviation, as appropriate
APACHE Acute Physiology and Chronic Health Evaluation, APS acute physiology score, COPD chronic obstructive pulmonary disease, ICU intensive care unit
a Modified Charlson Index is calculated including age
b Overall Chi-square test calculated for the number of patients per group that had received a class of antibiotics (as indicated in Fig. 1)
Baseline characteristics Normal microbial diversity  
(Shannon index < 4)
High microbial diversity  
(Shannon index > 4)
P value
Patients 17 17
Demographics
  Age (years) 65.12 ± 13.37 62.94 ± 10.96
  Gender (male) 8 (47.1%) 8 (47.1%)
  Body mass index 27.09 ± 5.78 25.72 ± 4.33
  Race (white) 15 (88.2%) 15 (88.2%) 1
Admission
  Medical admission 15 (88.2%) 12 (70.2%) 0.41
  Length of hospital stay prior to ICU  
admission
1 [0–2] 0 [0–2] 0.70
  Admission diagnosis sepsis 13 (76.5%) 12 (70.6%) 0.63
Chronic comorbidity
  None 5 (29.4%) 4 (23.5%) 1
  Cardiovascular compromise 6 (35.3%) 4 (23.5%) 0.72
  COPD 2 (11.8%) 2 (11.8%) 1
  Diabetes mellitus 3 (17.6%) 2 (11.8%) 1
  Hypertension 8 (47.1%) 6 (35.3%) 0.74
  Malignancy (non-metastatic solid) 3 (17.6%) 3 (17.6%) 1
  Renal insufficiency 3 (17.6%) 2 (11.8%) 1
  Respiratory insufficiency 3 (17.6%) 2 (11.8%) 1
  Modified Charlson Comorbidity Indexa 4 [3–6] 4 [3–5] 0.74
Severity of disease on ICU admission
  APACHE IV score 71 [59–91] 95 [79–107] 0.079
  APACHE APS 62 [47–80] 82 [64–96] 0.12
  SOFA score 8 [5.5–10] 8 [5–10] 1
  Mechanical ventilation 12 (70.6%) 15 (88.2%) 0.40
  Organ failure 15 (88.2%) 15 (88.2%) 1
  Number of organs failing
    1 4 (23.4%) 5 (29.4%) 1
    2 7 (41.2%) 6 (35.3%) 1
    ≥3 4 (23.5%) 4 (23.5%) 1
  Shock 7 (41.2%) 9 (52.9%) 0.71
Antibiotics used prior to sampleb 0.95
66
also with ICU mortality in critically ill patients [12]. Our 
data argue against the usefulness of the F/B-ratio as a 
microbiota marker in critically ill patients, as both Fir-
micutes and Bacteroidetes can be strongly but equally 
decreased. For example, patients no. 6 and 34 in our 
study had normal F/B-ratios, while still being colonized 
at 38 and 25%, respectively, with Proteobacteria. We also 
observed a relative increase in Gram-negative bacteria in 
11 patients. A decreased Gram-positive/Gram-negative 
ratio may be indicative of an increased inflammatory gut 
status as Gram-negative bacteria produce lipopolysac-
charides, some of which are powerful endotoxins.
This study has a number of limitations. As the study 
started in 2012, sepsis was not defined according to the 
most recently proposed criteria, including organ fail-
ure [36]. However, most patients likely meet these cri-
teria considering that we exclusively studied patients in 
need of intensive care [36]. It should be emphasized that 
the sample size is limited and the heterogeneity of criti-
cally ill patients substantial; these two limitations make 
it challenging to establish a potential causal relationship 
between microbiota composition and prognosis. Fur-
thermore, fecal sampling is trying, as many patients do 
not defecate. In future studies, rectal swabs could pro-
vide a suitable alternative as these have been shown to 
provide data comparable to stool samples [37]. The sin-
gle fecal sample studied here should be complemented 
by longitudinal analyses to provide a dynamic view of the 
microbiota. It should also be kept in mind that fecal sam-
ples do not provide information about the microbiota in 
the upper gastrointestinal tract. Lastly, the viral and fun-
gal microbiomes were not addressed in this study. This 
should be a key area of future studies, as these may com-
prise an important part of the microbiota in ICU patients.
Fig. 4 Firmicutes/Bacteroidetes ratio (F/B-ratio) and Gram-positive/Gram-negative bacteria ratio are not associated with short- and long-term 
survival in an exploratory setting. a The F/B-ratio was calculated from healthy subjects (dotted horizontal lines range of F/B-ratio in healthy subjects) 
and from all 34 critically ill patients. and plotted against survival at 4 time points. b Survival data were collected at four time points: during ICU stay 
(ICU) and at 30 and 90 days and 1 year (d30, d90, 1y, respectively). c The ratio of total Gram-positive/Gram-negative bacteria was calculated from 
healthy subjects (dotted horizontal lines range of ratio of Gram-positive/Gram-negative bacteria in health subjects. d Survival data collected at same 
time points as for b. b, d Data are presented as box-and-whisker plots, with median (horizontal line in box), interquartile range (ends of box), and range 
(whiskers). Black boxes Healthy subjects, white boxes surviving ICU patients, gray boxes non-surviving ICU patients
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In summary, we found striking abnormalities of the 
intestinal microbiota in both septic and non-septic criti-
cally ill patients, with a large interindividual variation and 
low bacterial diversity. Numerous questions remain to be 
answered, including: To what extent does microbial dis-
turbance influence dietary needs, metabolic status, intes-
tinal permeability, and immunity in critically ill patients? 
Equally important is the question: How might the 
observed microbiota shifts be leveraged, not only by devel-
oping diagnostic and prognostic markers but also thera-
peutically? Fecal microbiota transplantation is a feasible 
and effective treatment option for severe C. difficile infec-
tion in the ICU [38] and could also become the next big 
breakthrough in the fight against multi-drug resistant bac-
teria [3]. Two case reports have recently been published on 
the successful use of fecal microbiota transplantation in 
patients with therapy-resistant sepsis and diarrhea [39, 40]. 
This success raises hope for simple and effective adjunctive 
therapies based on our expanding knowledge of the gut 
microbiota that might benefit critically ill patients.
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